Published December 2007
| Version v1
Journal article
[Metabolic fatty liver diseases: hepatic consequences of the metabolic syndrome].
Contributors
Others:
- Centre méditerranéen de médecine moléculaire (C3M) ; Université Nice Sophia Antipolis (1965 - 2019) (UNS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UniCA)
- Centre Hospitalier Universitaire de Nice (CHU Nice)
- Hôpital Archet 2 [Nice] (CHU)
- Pôle Digestif ; Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital l'Archet
Description
Metabolic fatty liver diseases (Non Alcoholic Fatty Liver Diseases-NAFLD) are liver abnormalities (steatosis and steatohépatitis) commonly related to visceral obesity and to the metabolic syndrome. The pathogenesis of metabolic fatty liver diseases is most probably linked to the adipose tissue insulin resistance with a very high free fatty acids release, an abnormal secretion of factors produced by the adipose tissue (adipokines) and a low grade of chronic inflammation. The link between metabolic fatty liver diseases and the metabolic syndrome is further supported by epidemiological studies, as well as the frequently encountered cardio-vascular complications in both diseases. Changes in lifestyle with dietary restriction and increased physical activity are mandatory and similar for both conditions. Drugs such as thiazolidinediones, known to reduce insulin resistance and inflammation, still need further evaluation.
Abstract
International audienceAdditional details
Identifiers
- URL
- https://hal.science/hal-04496794
- URN
- urn:oai:HAL:hal-04496794v1